Informazioni sul prodotto
- Linagliptin Dimer Impurity,8-[(3R)-3-Amino-1-piperidinyl]-1-[[4-[[2-[[8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-1-yl]methyl]-1,4-dihydro-4-methyl-4-quinazolinyl]methyl]-2-quinazolinyl]methyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione
- 8-((R)-3-Aminopiperidin-1-yl)-1-((4-((2-((8-((R)-3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)-4-methyl-1,4-dihydroquinazolin-4-yl)methyl)quinazolin-2-yl)methyl)-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
Impurity Linagliptin Dimer Impurity
Stability Light Sensitive
Applications Linagliptin Methyldimer inhibits dipeptidylpeptidase-IV (DPP-IV) and may be used in the treatment of type 2 diabetes.
References Prabavathy, N. et al.: Int. J. Pharm. Bio. Sci., 2, 438 (2011); Deacon, C.F.: Diab. Obes. Metab., 13, 7 (2011);
Proprietà chimiche
Richiesta tecnica su: TR-L465910 Linagliptin Methyldimer
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.